Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy in a Predominantly Non-Asian Population:...

Area of Science:

• Ophthalmology
• Retinal Diseases
• Vascular Biology

Background:

• Neovascular polypoidal choroidal vasculopathy (PCV) is a significant cause of vision loss.
• Treatment options for PCV in non-Asian populations require further investigation.
• Intravitreal aflibercept (IAI) has shown promise in treating neovascular eye conditions.

Purpose of the Study:

• To assess the safety and efficacy of intravitreal aflibercept injections for treating neovascular PCV.
• To evaluate treatment outcomes in a predominantly non-Asian patient cohort.
• To determine the impact of IAI on visual acuity and retinal anatomy.

Main Methods:

• An open-label, prospective, nonrandomized clinical trial was conducted.
• Twenty eyes with neovascular PCV received 2.0 mg of IAI monthly for 3 months, followed by bi-monthly injections for 12 months.
• Visual acuity and central subfield thickness (CST) were primary outcome measures.

Main Results:

• A mean improvement of +9 ETDRS letters in best-corrected visual acuity was observed at 1 year.
• A mean reduction of 70 µm in central subfield thickness (CST) was achieved.
• No serious ocular adverse events were reported during the study period.

Conclusions:

• Intravitreal aflibercept injections demonstrated favorable visual, anatomic, and safety outcomes for neovascular PCV in a predominantly non-Asian population.
• IAI is a safe and effective treatment option for this condition.
• Further research may explore long-term efficacy and treatment regimens.